Sildenafil drug interactions matter because some combinations can cause dangerous blood-pressure changes and others can increase drug exposure or adverse effects. A safe prescription requires a review of medications used for chest pain, pulmonary hypertension, prostate symptoms, blood pressure and a range of infections or chronic conditions. The same caution applies to nonprescription substances that patients may not think of as medications.
This page provides a drug-class overview rather than a personalized interaction checker. It distinguishes absolutely contraindicated combinations, combinations requiring specific monitoring or prescribing adjustments, and other ED therapies that should not be stacked. The dedicated nitrate–sildenafil interaction page gives a deeper explanation of nitrate risk.
Sildenafil used for erectile dysfunction is not interchangeable with sildenafil prescriptions for pulmonary arterial hypertension (PAH). A patient should show the clinician and pharmacist a complete list of actual products and indications rather than relying on the active ingredient name alone. The overall ingredient context is provided on the sildenafil hub.
A contraindication means a medicine should not be used in the specified combination. Other interactions may call for cautious prescribing, dose adjustment, clinical monitoring or review of alternatives. The seriousness depends on the drug and the individual’s health; all interactions are not equivalent.
A medication-reconciliation conversation should include prescription drugs, OTC medicines, supplements, recreational substances and treatments from other clinicians. The prescriber—not an online list—decides what is safe or whether sildenafil is appropriate.
| Drug class or example | Main concern | General U.S. labeling context |
|---|---|---|
| Organic nitrates and nitric-oxide donors | Potentially profound hypotension | Contraindicated |
| Riociguat | Excessive cGMP-mediated blood-pressure lowering | Contraindicated |
| Alpha-blockers | Symptomatic hypotension, dizziness or faintness | Special prescribing precautions |
| Strong CYP3A4 inhibitors | Increased sildenafil exposure | May require label-specific prescribing adjustment |
| Ritonavir (specific CYP3A4 interaction) | Markedly increased sildenafil blood exposure | Viagra ED label: maximum 25 mg in any 48-hour period; clinician must manage |
| Other PDE5 inhibitors | Combined effects and lack of established safety | Do not combine independently |
| Other antihypertensives | Additional blood-pressure reduction | Clinical review required |
Sildenafil can markedly intensify the blood-pressure-lowering effect of organic nitrates and nitric-oxide donors. Examples may include nitroglycerin, isosorbide preparations and certain recreational nitrites known as “poppers.” These products must not be combined with sildenafil under its U.S. ED labeling.
Patients treated for angina or chest pain need explicit guidance before any ED prescription. If chest symptoms occur after sildenafil, emergency clinicians must be told when it was taken; a patient should not self-administer nitrates. See the dedicated nitrate page for the detailed topic.
Riociguat is a soluble guanylate cyclase stimulator used in selected pulmonary-hypertension conditions. Concurrent administration with sildenafil is contraindicated because both affect the nitric-oxide–cGMP pathway and can cause excessive blood-pressure reduction.
This restriction also shows why sildenafil ED content should not be applied to PAH regimens without specialist oversight. Patients should make sure each treating clinician knows about drugs prescribed by the others.
Alpha-blockers used for some prostate and cardiovascular conditions can add to sildenafil’s blood-pressure-lowering action. Dizziness, lightheadedness or fainting may occur in susceptible patients. The U.S. label includes precautions about clinical stability and starting conditions when the treatments are combined.
The presence of an alpha-blocker does not create a universal one-line dosing instruction for the public. The clinician must assess the particular products, timing, blood pressure and comorbidities; patients should not attempt their own adjustment. the dosage guide explains the difference between the prescribing framework and product strength.
Sildenafil is metabolized predominantly through CYP3A4, so inhibitors of this enzyme can raise systemic exposure. The U.S. Viagra ED label specifically discusses erythromycin, ketoconazole, itraconazole and saquinavir in its interaction guidance; the strength of an interaction and the recommended response vary by interacting medicine. These are prescribing considerations, not a reason for a reader to select an alternative strength on their own.
The label advises clinicians to consider a lower starting dose when certain strong CYP3A4 inhibitors or erythromycin are used. A medicine with multiple ingredients or a pharmacokinetic booster deserves review of the complete regimen. The sildenafil dosage page explains how general dosing rules differ from drug-specific adjustments.
Sildenafil can add to the blood-pressure-lowering effect of certain antihypertensive medicines. The degree of concern varies by drug, baseline blood pressure and cardiovascular status. Prescribers also assess whether sexual activity itself is advisable for a patient’s cardiac condition.
Symptoms such as fainting, marked weakness or chest pain after medication use require prompt medical assessment, with emergency care for severe symptoms. A person should tell emergency clinicians about recent sildenafil rather than assume all chest-pain treatments are safe after an ED tablet.
Sildenafil should not be stacked with tadalafil, vardenafil, avanafil or other PDE5-containing treatments without medical direction. Combining drugs can increase pharmacologic effects and adverse-event risk, and the safety of combinations cannot be assumed from each individual drug’s approval.
If the current medicine is not working or is poorly tolerated, discuss alternatives with the prescriber. For an editorial overview of the options use the ED medicine directory, and for specific ingredient contrasts use sildenafil versus tadalafil.
Alcohol can complicate blood-pressure symptoms and erectile response, especially with heavy consumption. Products sold as unregulated “male enhancement” supplements may contain undeclared prescription ingredients, making interaction risks difficult to predict. Recreational nitrites must be explicitly disclosed because of their nitrate-like dangers.
A complete medication list should include supplements and nonprescription substances. the alcohol guide covers the drinking question in context rather than mixing it into a list of prescription drug classes.
The safest workflow starts with the accurate names, strengths and schedules of every medicine; current symptoms and blood-pressure history; major liver or kidney conditions; and the intended ED indication. A clinician can distinguish a true contraindication from a precaution that requires monitoring or another treatment.
The pharmacist can verify dispensed products and identify potential interaction alerts, but should not be bypassed by an online seller promising “no questions asked.” For legitimate prescriptions use the prescription guide; for the dispensing context see licensed online-pharmacy checks.
A prolonged erection lasting more than four hours is an emergency. Sudden loss of vision or hearing requires stopping sildenafil and prompt medical attention. Fainting, severe hypotensive symptoms or chest pain should also be assessed urgently according to severity.
A patient who seeks emergency care after sildenafil use should say when it was taken and provide their medication list. The broader symptom-based discussion is on the side-effects page.
Sildenafil may be prescribed for ED or pulmonary arterial hypertension under distinct labeling. A medication list that merely says “sildenafil” may not tell the entire story, especially if another specialist is managing PAH therapies. Clinical teams must reconcile the indication and co-prescriptions.
Sildenafil ED guidance cannot authorize substitutions, frequency changes or combined therapies for PAH. Treatment of pulmonary hypertension requires disease-specific specialist management.
Organic nitrates or nitric-oxide donors and riociguat are contraindicated with sildenafil.
The combination can produce a potentially severe drop in blood pressure.
Yes. They may increase the risk of symptomatic hypotension, requiring clinician-specific precautions.
Certain medicines that inhibit CYP3A4 can increase sildenafil exposure. The exact product needs clinical review.
The U.S. Viagra ED label reports approximately elevenfold higher sildenafil exposure with ritonavir and specifies no more than a single 25 mg dose in any 48-hour period. A prescriber must review the actual regimen; do not self-adjust either medicine.
Do not combine PDE5 inhibitors independently. A prescriber should evaluate any proposed treatment changes.
Yes. Provide a complete list, including supplements and recreational substances, because interaction and hidden-ingredient risks may matter.
Seek urgent medical care and tell clinicians that sildenafil was taken and when; do not self-administer nitrates.